From the helm: Amplia Therapeutics (ASX:ATX), CEO & MD, Christopher Burns & Bell Potter Analyst, Thomas Wakim.

Bell Direct
March 20, 2026

In this episode of From the Helm, Grady is joined by Amplia Therapeutics (ASX:ATX) CEO & MD Dr Christopher Burns & Bell Potter Analyst Thomas Wakim to unpack the ongoing clinical trials for their prospective treatment drug for pancreatic cancer, and its substantial market opportunities in the US.

Market Update 16 April

Jessica Amir
April 16, 2020

Morning Bell 15 April

Jessica Amir
April 15, 2020

Market Update 9 April

Jessica Amir
April 9, 2020

Weekly Wrap 9 April

Jessica Amir
April 9, 2020

Market Update 8 April

Jessica Amir
April 8, 2020

Morning Bell 7 April

Jessica Amir
April 7, 2020

Morning Bell 6 April

Jessica Amir
April 6, 2020

Market Update 3 April

Jessica Amir
April 3, 2020

Weekly Wrap 3 April

Jessica Amir
April 3, 2020

SMSF Trust Deed

Bell Direct
April 2, 2020

Switching your SMSF to us

Bell Direct
April 2, 2020

Setting up your SMSF

Bell Direct
April 2, 2020